Cornelius J R, Soloff P H, George A, Ulrich R F, Perel J M
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PA 15213.
Psychopharmacol Bull. 1993;29(2):333-7.
We report the first double-blind, placebo-controlled continuation study comparison of a neuroleptic (haloperidol < or = 6 mg), monoamine oxidase inhibitor (MAOI) antidepressant (phenelzine < or = 90 mg), and placebo in 54 patients with borderline personality disorder. Continuation medication trials of 16 weeks followed 5 weeks of acute therapy. Haloperidol continued to be effective beyond the acute phase only for the treatment of irritability. Higher levels of depression, hypersomnia, and leaden paralysis were noted in the haloperidol group than in the phenelzine and placebo groups. The dropout rate during the first half (8 weeks) of the continuation study was significantly higher for the haloperidol group (64%) than for the placebo group (28%) (p < .05). Phenelzine demonstrated very modest efficacy beyond that noted in the acute phase for the treatment of depression and irritability. Phenelzine was shown to have an activating effect on measures of excitement and reactivity.
我们报告了第一项针对54例边缘型人格障碍患者进行的双盲、安慰剂对照的延续性研究，该研究比较了一种抗精神病药物（氟哌啶醇≤6毫克）、一种单胺氧化酶抑制剂（MAOI）抗抑郁药（苯乙肼≤90毫克）和安慰剂的效果。在5周的急性治疗之后进行了为期16周的延续性药物试验。仅在治疗易怒方面，氟哌啶醇在急性期之后仍继续有效。与苯乙肼组和安慰剂组相比，氟哌啶醇组的抑郁、嗜睡和铅样麻痹水平更高。在延续性研究的前半段（8周），氟哌啶醇组的脱落率（64%）显著高于安慰剂组（28%）（p<0.05）。苯乙肼在治疗抑郁和易怒方面，其疗效仅略高于急性期所观察到的效果。苯乙肼对兴奋和反应性指标具有激活作用。
